

# Nanosponges: A Emerging trend in the Targeted Drug Delivery System

Abhidnya S. Shirke, Aditya A. Walunj, Ajay C. Ahire, Dinesh Burute, Mr. Sachin M. Bhalekar  
Samarth Institute of pharmacy, Belhe, Maharashtra, India

**Abstract:** *Nanosponges are small three dimensional porous structure about the size of nanometer that can contain many different drugs. The long term attempt to create efficient, targeted medication delivery system have been delayed by the complexity of the chemical interaction required to build drug delivery system. The most of the drugs come from the synthetic chemistry posses poor water solubility and approximately 70% of drug fall under such category. Nanosponges is being priorities to control the delivery of drug/API/Phytoconstituent to particulate the skin targeting. The nanosponges porous construction allow it to trap drug molecular and release them gradually. Nanosponges are used for target drug delivery system (TDDS). This review article deals with the general introduction, mechanisum of action, advantages, Disadvantages, preparation methodologies and evaluation parameter*

**Keywords:** Nanosponges, Trageted drug delivery system, Crosslinker, Topical targeted, controlled release

## I. INTRODUCTION

The drug delivery technology has definite a new interest for medication by providing them new life through their therapeutic targets. Targeted drug Administration also known as Smart drug delivery (1).

In 1959, Caltech physicist Richard P. Feynman provided an informed opinion on the topic of nanomaterial.

Any substance with at least dimension between 1 and 100 nmis considered as nanomaterial.

Biocompatible material, functionalized textiles, UV-protective coating and agent that speed up the killing of germs , carry medicine, transfer DNA & immobilized enzyme are just some of the many product that make use of nanoparticle(2).

The conventional drug delivery technique involve drug absorption across a biological membrane, whereas the targeted release in system involve drug release in a dose form. Many drug -delivery system such as nanoparticle, nanoemulsion, nanosuspension, nanosponges and so on, have now been produce employing nanomedicine technology and are associated with several benefit including enhanced bioavailability. (3)




Fig 1:- Formation of Nanosponges

Nanosponges are a new type of hyper cross linked polymer -based colloidal structure consisting of solid nanoparticle with colloidal and nanosized cavities.

Changes in the pharmacokinetic characteristics of the active Component are responsible for the increased bioavailability of drugs when delivered on nanosponges. This is achieved by improving the solubility of pharmaceutical in water, so facilliting a controlled release over time. In order to create nanosponges, Polyesters ( cyclodextrin) are blended with cross linking agent (Fig 1) to form a unique nanostructured material (4).

These polyesters and cross -linker are combined in a liquid form to create Nanosponges. Polyester is biodegradable. Therefore, it disintegrate when ingested. Toxic drug molecular are released when the Framework of the Nanosponges break down (5).

Most drugs for the formulation of nanosponges belongs to the biopharmaceutical classification system (BSC) Class II drugs and the drugs which possess extensive first-pass metabolism (6)

Table 1:- Biopharmaceutical classification system

Class	Solubility	Permeability
<b>I</b>	<b>High</b>	<b>High</b>
<b>II</b>	<b>Low</b>	<b>High</b>
<b>III</b>	<b>High</b>	<b>Low</b>
<b>IV</b>	<b>Low</b>	<b>Low</b>

**Objectives:-**

- To enhance the solubility of poorly soluble drugs.
- To increase the bioavailability of the drugs.
- To increase, prolong and control release of a drug.

**Advantages(7-12)**

- The properties of nanosponges include not being abrasive, poisonous, Mutagenic, Allergic or irritating.
- Nanosponges can let the drug molecules out in a way that can be predicted.
- It is possible to achieve extended release action for up to 12 h.
- Nanosponges complexes are stable at temperature of 130° C and pH levels from 1 to 11.
- Nanosponges increase the bioavailability of the drug, e.g, Erlotinib hydrochloride.
- Nanosponges protect the molecules from degrading, e.g, Doxorubicin.
- These are free flowing substance.

**Disadvantages :-**

- Nanosponges encapsulate small molecules (more than 500 dalton) , which is not suitable for larger molecules. (13)
- Nanosponges may be crystalline or para crystalline in nature.
- Nanosponges can encapsulate small molecules but aren't good for encapsulating larger molecules. Sometimes, dose dumping can happen. (14)

Drug	Nanosponges vehicle	Indication	Study	In vitro/ In vivo mathematical model	Reference
Paclitaxel	Beta - cyclodextrin	Cancer	Bioavailability	Sprague dawley rats	15
Camptothecin	Beta- cyclodextrin	Cancer	Heamolytic activity	MCF 7 Cell line	16,17
Tamoxifen	Beta - cyclodextrin	Breast cancer	Cytotoxicity	MCF7 Cell	18
Itraconazole	Beta -cyclodextrin and copolyvidonum	Anti fungal	Saturation solubility study	Higuchi model	19
Voriconazole	EC, PMMA, PVA		Anti-fungal	Drug release Experiment	15
Econazole nitrate	EC	Anti-fungal	Irritation study	Rat	20
Dexamethasone	Beta -cyclodextrin	Brain tumor	Drug release study	Dialysis bag technique in vitro	21

EC: Ethyl cellulose, PMMA: Polymethyl methacrylate,

Table 1:- Examples of Nanosponges

DOI: 10.48175/568

**Preparation method for Nanosponges :-**

The method employed for Loading drug into the nanosponges structure is dependent on the nature of the polymer, drug proportion, and Cross linker(22)

Melt Method

Solvent method

Ultrasound assisted synthesis.

**Melt Method:-**The basis for the melt method is to carry out reaction with a cross linker. All ingredient put in a 250 ml flask and heated an elevated temp, and stirred on the magnetic stirrer to proceed with reaction.

The prepared mixture is allowed to cool down and need to wash by using a solvent. Repeated washing is required to remove unreacted Excipient from the product.

Table 2:- Literature for Nanosponges prepared using melt method

Drug	Excipient	Outcome	Reference
Gabapentin	Ethyl cellulose, diphenyl carbonate, polyvinyl pyrrolidine, xantum gum, sucrose, talc, citric acid, and methylparaben	It shows a sustained release effect	23
Curcumin and caffeine	Dimethyl carbonate(DMC), guar gum and carbopol-934	Sustained drug release was achieved till the end of 12 h by preparing NS- based topical gel.	24
Econazole nitrate	Beta -cyclodextrin, N – carbonyl diimidazole (CDI) , carbopol -934 , triethanolamine, methyl paraben, propylene glycol, n- methyl -2- pyrrolidine.	It work as a permeation enhancer.	25
Paracetamol, aceclofenac, caffeine	Beta – cyclodextrin, dimethyl carbonate, cross povidone	It enhance drug solubility	26

**Solvent method**

The necessary solvent is combined with the polymer primarily in a polar aprotic solvent, such as dimethyl formamide Or dimethyl sulfoxide. This mixture is then added in excess amount to be cross linker, with a desirable molar ratio of 4-16 . The reaction is carbonate and carbonyl di- imidazole are two cross linker that may be preferred(27). When the reaction is finished, the solution is allowed to cool at room temperature before the product is added to extra bi – distilled water, recovered by filtration under vaccum, and purified at the same time by extended soxhlet extraction with ethanol. The product is then vaccume dried and mechanically milled to generate a uniform powder. (28)

Table 3:- literature for Nanosponges prepared using solvent method.

Drug	Excipient	Outcome	Reference
Econazole nitrate	Ethyl cellulose, polyvinyl alcohol, dichloromethanol, and carbopol 934	It shows extended-relese effect	29
Telmisarta	Beta -cyclodextrin, diphenyl carbonate	Enhanced solubility and bioavailability of drug	30
Lemon grass oil	Ethyl cellulose, polyvinyl alcohol, carbopol	It show a sustained release effect	31
Efavirenz	Beta cyclodextrin, sodium lauryl sulfate(SLS), and diphenyl carbonate	It enhance the solubility and dissolution of the drug.	32

**Ultrasound assisted synthesis:-**

A flask is all that's needed for a reaction between cross linker and polymer, and no solvent is required. The flask containing a mixture is placed in an ultrasound bath containing water heated to 90° and sonication occur there for 5 hour. After the material has cooled to normal temperature, it is divided into smaller pieces. The non – reactive polymer is removed during rising, and the ethanol used to create the nanosponges is refined using a soxhlet apparatus(33)

Table 4:- Literature review for Nanosponges prepared using Ultrasound assisted synthesis

Drug	Excipient	Outcome	Reference
Camptothecin	Beta – cyclodextrin, diphenyl carbonate	It increase stability and prolonged drug release kinetics.	34
Methotrexate	Diphenyl carbonate, beta – cyclodextrin and fluronic F 127	Drug Intra – articular retention time approved by this method.	35

**Nanosponges characterization**

**Solubility studies:-**

The dissolution and bioavailability of the medicine may be modulated with the use of inclusion strategies. The solubility method is often used to investigate NS inclusion complexes. Solubility assays may be performed to determine how the drug dissolve, what variable impact their solubility, and the pH of molecules. (36)

**Assessing Loading effectiveness and production yeild:-**

Subtracting the un -entrapped drug from the total drug amount yeild the prepared Nanosponges loading efficiency. By isolating un-entrapped drug that has been evaluate by any applicable method of analysis, the effectiveness of the drug entrapped will be ascertained. (37)

Gel filtration, dialysis and ultra – centrifugation are the technique used to separate un- entrapped drug.

$$\text{Loading efficiency} = \frac{\text{Actual drug content}}{\text{Theoretical drug content}} \times 100$$

$$\text{Production yeild} = \frac{\text{Practical mass of NS}}{\text{Theoretical mass(drug+polymer)}} \times 100$$

**Microscopy studies:-**

Scanning Electron Microscopy (SEM) And Transmission electron microscopy (TEM) are used for microscopy studies. (38)

**Porosity:-**

Percent porosity is given by following equation=

$$\% \text{ Porosity} = \frac{\text{Bulk volume} - \text{Actual volume}}{\text{bulk volume}} \times 100$$

**FTIR Spectroscopy:-**

FTIR is used to determine the pH of the formulation. (39)

Drug used for topical preparation of Nanosponges are as follows:-

The following table highlight the excipient used, various method of preparation of Nanosponges and outcome of the research work is carried out by multiple researchers.

Drug	Excipient	Method of preparation	Result	Reference
Gliclazide	Polyvinyl alcohol, Dichloromethane, Triethyl citrate	Emulsion solvent diffusion method	It improve the dissolution and bioavailability profile of the poorly water-soluble drug	40
Lamotrigine	Ethyl cellulose, polyvinyl alcohol	Emulsion solvent diffusion method	It enhance the solubility and dissolution rate	41
Fluconazole	Ethyl cellulose, polyvinyl alcohol, ethanol, carbopol-940, Propylene glycol and	Emulsion solvent diffusion method	The better retention ability of Nanosponges and improve patient compliance	42

	triethanolamine			
Cinnamon oil	Polyvinyl alcohol, carbopol-940 and ethyl cellulose	Emulsion solvent diffusion method	Effective stable topical dosage form with improved and sustained release characteristics	43

## II. CONCLUSION

Nanosponges are a novel kind of biocompatible, flexible drug carrier due to their capacity to form inclusion and non-inclusion complexes with hydrophobic and hydrophilic medication.

They are a colloidal carrier that have recently been created and proposed for drug delivery because they can be used to solubilize poorly water soluble drugs, providing delayed release, enhance bioavailability of drugs, and in certain cases changes their pharmacokinetic properties.

For targeting of the drug and to achieving desired drug release in a predictable manner, nanosponges were found to be excellent.

The Pharmaceutical industry might benefit greatly from clinical studies demonstrating the safety of medication administered using the Nanosponges in human.

## ACKNOWLEDGMENT

The author is thankful to the management of the progressive education society for providing the necessary facility to carry out the literature survey and related work.

## REFERENCES

- [1]. Muller RH, Kech CM. Challenges and solution for the delivery of biotech drugs: a review of drug nanocrystal technology and lipid nanoparticles. *J Biotechnol* 2004;113:151-70.
- [2]. Mark AM, Przemyslaw R, Greg C, Greg S, Akram S, Jonathan F et al. In vivo human time exposure study of orally dosed commercial silver nanoparticles. *Nanomedicine: nanotechnology, biology, and medicine*. 2014;10:1-9.
- [3]. Rahi N, Kumar K. Nanosponges: a new era versatile drug delivery system. *Univ J Pharma Res* 2017;2:30-3.
- [4]. Vicky VM, Rodney S, Ajay S, Hardik RM. Introduction to metallic nanoparticles. *J Pharm Bioallied Sciences*, 2010;2(4):282-289.
- [5]. Vyas SP, Khar RK. Novel carrier system, Targeted and controlled drug delivery. 1<sup>st</sup> ed. CBS publishers, New Delhi 2002,332-413.
- [6]. Lee JS, Oh H, Kim S, Lee JH, Shin YC, Choi WI. A novel chitosan nanosponges as a vehicle for transdermal drug delivery. *Pharmaceutics* 2021;13:1329.
- [7]. Rajeshwari C, Alka A, Javed A, Khar RK. Cyclodextrin in drug delivery: An update review. *AAPS Pharm Sci Tech* 2013;6:329-57.
- [8]. Sharma R, Walker RB, Pathak K. Evaluation of the kinetics and mechanism of drug release from econazole nitrate nanosponges loaded carbopol hydrogel. *Indian J Pharm Educ* 2011;45:25-31.
- [9]. Swaminathan S, Vavia P, Trotta F, Torne S. Formulation of beta cyclodextrin based nano sponges of itraconazole. *J Incl Phenom Macro Chem* 2007;57:89-94.
- [10]. Dora CP, Trotta F, Kushwah V, Devasari N, Singh C, Suresh S, et al. Potential of erlotinib cyclodextrin nanosponges complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. *Carbohydr Polym* 2015;137:339-49.
- [11]. Balwe MB. Nano sponges: a novel drug delivery system. *Res J Pharm Dosage Form Technol* 2020;12:261-6. doi: 10.5958/09754377.2020.00043.9
- [12]. Wong VN, Fernando G, Wagner AR, Zhang J, Kinsel GR, Zaischer S, et al. Separation of peptide with polyionic nanosponges for MALDI-MS analysis. *Langmuir* 2009;25:1459-65.
- [13]. Jain A, Prajapati SK, Kumari A, Mody N, Bajpai M. Engineered nanosponges as versatile biodegradable carrier: An insight. *J Drug Deliv Sci Technol* 2020;57:1-38.

- [14]. Nowack B, Krug HF, and Height M. 120 years of nanosilver history: implications for policy makers. *Environ Sci Technol*, 2011;45:1177-1183.
- [15]. Torne SA, Ansari KA, Vavia PR, Trotta G, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel loaded nanosponges. *Drug Deliv* 2010;17:419-25.
- [16]. Minelli R, Cavalli R, Fantozzi R, Dianzani C, Pettazoni P, Ellis L, et al. Abstract 4431: Antitumor activity of Nanosponges-encapsulated camptothecin in human prostate tumor. *Cancer Res* 2011;71(8\_supplement):4431. doi:10.1158/1138-7445.AM2011-4431.
- [17]. Swaminathan S, Pastoro L, Serpe L, Trotta F, Vavia P, Aquilano D, et al. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. *Eur J Pharm Biopharm* 2010;74:193-201.
- [18]. Alongi J, Poskovic L, Frache A, Trotta F. Role of beta-cyclodextrin nanosponges in polypropylene photooxidation. *Carbohydrate polymer* 2011;86:127-35.
- [19]. Swaminathan S, Vavia P, Trotta F, Torne S. Formulation of beta-cyclodextrin based nanosponges of itraconazole. *J Incl Phenom Macro Chem* 2007;57:89-94.
- [20]. Sharma R, Walker RB, Pathak K. Evaluation of the kinetics and mechanism of drug release from econazole nitrate nanosponges loaded carbopol hydrogel. *Indian J Pharm Education Res* 2011;45:25-31
- [21]. Lala R, Torat A, Gargate C. Current trends in beta-cyclodextrin based drug delivery system. *Int J Res Ayur Pharm* 2011;2:1520-6.
- [22]. Pawar S, Shende P, Trotta F. Diversity of beta-cyclodextrin based nanosponges for transformation of actives. *Int J Pharm* 2019;565:333-50.
- [23]. Rao MR, Bhingole RC. Nanosponges based pediatric-controlled released dry suspension of gabapentin for reconstitution. *Drug Dev Ind Pharm* 2015;41:2029-36.
- [24]. Irivreni P, Gupta NV, Osmani RA, Balamuralidhar V. Design and development of nanosponges loaded topical gel of Curcumin and caffeine mixture for augmented treatment of psoriasis. *DARU* 2020;28:489-506.
- [25]. Shrivastava S, Mahor A, Singh G, Bansal K, Singh PP, Gupta R, et al. Formulation and development, in vitro and vivo evaluation of topical hydrogel formulation of econazole nitrate-loaded beta-cyclodextrin nanosponges. *J Pharm Sci* 2021;110:3702-14.
- [26]. Moin A, Roohi NK, Rivzi SM, Ashraf SA, Siddiqui AJ, Patel M, et al. Design and formulation of polymeric nanosponges tablet with enhanced solubility for combination therapy. *RSC Adv* 2020;10:34869-84.
- [27]. Alongi J, Poskovic M, Frache A, Trotta F. Role of beta-cyclodextrin nanosponges in polypropylene photooxidation. *Carbohydr Polym* 2011;86:127-35.
- [28]. Singh R, Nitin B, Jyostana M, Horemats N. Characterization of cyclodextrin inclusion complexes – a review. *J Pharm Sci Technol* 2010;2:171-83.
- [29]. Sharma R, Walker RB, Pathak K. Evaluation of the kinetics and mechanism of drug release from econazole nitrate nanosponges loaded carbopol hydrogel. *Indian J Pharm Res Educ* 2011;45:25-31.
- [30]. Rao MR, Bajaj A, Khole I, Munjapara G, Trotta F. In vitro and in vivo evaluation of beta-cyclodextrin based nanosponges of telmisartan. *J Incl Phenom Macrocycl Chem* 2012;77:135-45.
- [31]. Aldawsari HM, Badr -Eldin SM, Labib GS, El-Kamel AH. Design and formulation of a topical hydrogel integrating lemongrass-loaded nanosponges with an enhanced antifungal effect: In vitro/in vivo evaluation. *Int J Nanomedicine* 2015;10:893-902.
- [32]. Rao MR, Shirsath C. Enhancement of bioavailability of non-nucleoside reverse transcriptase inhibitor using nanosponges. *AAPS Pharm Sci Tech* 2016;18:1728-38.
- [33]. Subramanian S, Singireddy A, Krishnamoorthy K, Rajappan M. Nanosponges: a novel class of drug delivery system – review. *J Pharm Sci*, 2012, 15(1):103-111.
- [34]. Potdar S, Ingale V, Kulkarni N, Munde M, Dhole S. Insight on development and evaluation of nanosponges drug delivery for improved therapeutic effectiveness. *Asian J Pharm Technol* 2022;12:129-5.
- [35]. Banjare N, Gautam L, Behera C, Gupta PN, Vyas S, Vyas SP. Cyclodextrin nanosponges based site retentive controlled release system for treatment of rheumatic arthritis. *J Drug Deliv Science Technol* 2020;60:101973.
- [36]. Farrell D, Limaye S, Subramanian S. Silicon nanosponges particles. U. S. Pat 0,251,561.



- [37]. Patil BS,, Mohite SK. Formulation design and development of Artesunatenanosponges. Eur J pharm Res 2016;3:206-11.
- [38]. Shringirishi M, Prajapati SK, Mahor A, Alok S, Yadav P, Verma A. Nanosponges: A potentialNanocarrier for novel drug delivery -a review. Asian Pacific J Trop Dis 2014;4:S519-26.
- [39]. Tejashri G, Amrita B, DarshanaJ. Cyclodextrin based nanosponges for pharmaceutical use :A review. Acta Pharm 2013;63:335-58.
- [40]. Solunke RS, BorgeUR, Murthy K, Deshmukh MT, Shete RV. Formulation and evaluation of gliclazidenanosponges. Int J Appl Pharm 2019;11:181-9.
- [41]. Satpathy TK, Chaubey N, Brahma CK, Maheshwari M. Formulation and evaluation of lamotrigine loaded nanosponges. Res J paharmTechnol 2022;15:229-35.
- [42]. Ghanbarzadeh S, Arami S. Enhanced transdemal delivery of diclofenac sodium via conventional liposomes, ethosomes and transferosomes. Biomed res Int 2013:616810.
- [43]. Kuar M, NagpalM, singh M, Singh TG, AggrawalG, Dhingra GA. Improved antibacterial activity of topical gel-based on Nanosponge carrier of cinnamon oil Bioinpects 2021;11:23-32.